These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 10216068)

  • 1. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.
    Bagg A
    J Mol Diagn; 2002 Feb; 4(1):1-10. PubMed ID: 11826183
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
    Kockerols C; Valk PJM; Dulucq S; Nicolini FE; Mahon FX; Atallah E; Mauro MJ; Radich JP; Bernardi S; Russo D; Farina M; Mori S; Gambacorti-Passerini C; Civettini I; Lu L; Yeung D; Branford S; Colafigli G; Breccia M; Hogenbirk P; van Rosmalen J; Cornelissen JJ; Westerweel PE
    Am J Hematol; 2024 Aug; 99(8):1632-1635. PubMed ID: 38769689
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Hochhaus A; Saussele S; Rosti G; Mahon FX; Janssen JJWM; Hjorth-Hansen H; Richter J; Buske C;
    Ann Oncol; 2017 Jul; 28(suppl_4):iv41-iv51. PubMed ID: 28881915
    [No Abstract]   [Full Text] [Related]  

  • 4. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.
    Baccarani M; Efficace F; Rosti G
    Haematologica; 2014 Feb; 99(2):205-8. PubMed ID: 24497557
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.
    Rosenberg MW; Savage SL; Eide CA; Reister Schultz A; Cook RJ; Press RD; Rempfer C; Eickelberg G; Wilmot B; McWeeney SK; Tyner JW; Druker BJ; Tognon CE
    Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36307214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of p210
    Wang YY; Ding WJ; Jiang F; Chen ZX; Cen JN; Qi XF; Liang JY; Liu DD; Pan JL; Chen SN
    Oncol Lett; 2017 Nov; 14(5):5171-5178. PubMed ID: 29151902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review.
    Morozova EV; Vlasova YY; Pryanishnikova MV; Lepik KV; Afanasyev BV
    Biomark Insights; 2015; 10(Suppl 3):43-7. PubMed ID: 26673003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
    Beiske K; Burchill SA; Cheung IY; Hiyama E; Seeger RC; Cohn SL; Pearson AD; Matthay KK;
    Br J Cancer; 2009 May; 100(10):1627-37. PubMed ID: 19401690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.
    Kereskai L; Vass JA; Kneif M; Pajor L
    Pathol Oncol Res; 2003; 9(3):174-9. PubMed ID: 14530811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
    Lee YK; Lee DW; Kim YL; Lee S; Min CK; Kim YJ; Oh IH; Kim TG; Kim CC; Kim DW
    Int J Hematol; 2002 Aug; 76(2):180-5. PubMed ID: 12215018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic and clinical aspects of autologous stem cell transplantation with mobilized peripheral blood cells in chronic myelogenous leukemia.
    Frassoni F
    Curr Oncol Rep; 2000 Mar; 2(2):144-51. PubMed ID: 11122836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
    Miyamoto T; Weissman IL; Akashi K
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7521-6. PubMed ID: 10861016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and quantification of leukemia-specific rearrangements.
    Hochhaus A
    Methods Mol Med; 2002; 68():67-96. PubMed ID: 11901513
    [No Abstract]   [Full Text] [Related]  

  • 14. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.
    Moravcová J; Nádvorníková S; Lukásová M; Klamová H
    Blood; 1999 Nov; 94(10):3609-11. PubMed ID: 10610116
    [No Abstract]   [Full Text] [Related]  

  • 15. A nested RT-PCR assay to detect BCR/abl.
    Wasserman LM
    Methods Mol Med; 2004; 97():181-9. PubMed ID: 15064493
    [No Abstract]   [Full Text] [Related]  

  • 16. Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.
    Hughes TP; Branford S
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S266-71. PubMed ID: 19778851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The detection and significance of minimal residual disease in chronic myeloid leukemia.
    Radich JP
    Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
    Faderl S; Talpaz M; Kantarjian HM; Estrov Z
    Blood; 1999 May; 93(9):2755-9. PubMed ID: 10216068
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.